News of Note—Dynavax and Hilleman Labs

Here is some other vaccine news of note for this week.

> Dynavax is reportedly weighing strategic options such as a sale or licensing deal for its hepatitis B vaccine program. Reuters article

> Hilleman Labs won a grant worth about $700,000 to develop an oral cholera vaccine candidate. Release